How Accurate Is a DNA Test During Pregnancy?

Q: How accurate is a DNA test during pregnancy?

A DNA test during pregnancy, specifically non-invasive prenatal testing (NIPT), is over 99% accurate for detecting trisomy 21, with similarly high accuracy for other common chromosomal conditions. However, it is a screening test, not diagnostic, and results should be confirmed with CVS or amniocentesis if positive.

Learn how accurate NIPT is for detecting chromosomal conditions. US-based guide to DNA test accuracy during pregnancy, including cell-free DNA and carrier screening.

A DNA test during pregnancy—specifically non-invasive prenatal testing (NIPT)—is highly accurate, with detection rates exceeding 99% for common chromosomal conditions such as trisomy 21 (Down syndrome). NIPT analyzes cell-free DNA from the placenta circulating in the mother’s blood and is considered the most reliable screening option available in 2026. However, accuracy varies by the condition being tested, the fetal fraction, and whether the test is used for screening or diagnostic purposes. This guide explains the science behind NIPT accuracy, compares it to other prenatal screening methods, and helps you decide if a comprehensive prenatal screening panel is right for you.

What Is a DNA Test During Pregnancy?

The most common DNA-based prenatal screening is non-invasive prenatal testing (NIPT), also called cell-free DNA (cfDNA) testing. It is performed as early as 10 weeks of gestation and requires only a blood draw from the mother. The test screens for trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), and sometimes sex chromosome abnormalities. Some NIPT panels also include microdeletions and can reveal fetal sex. Because it is non-invasive, NIPT carries no risk of miscarriage, unlike diagnostic procedures such as chorionic villus sampling (CVS) or amniocentesis.

How Accurate Is NIPT?

NIPT is widely regarded as having the highest accuracy among prenatal screening tests. The table below summarizes typical performance for common conditions as reported in large US studies (2026 data reflect continued refinements in sequencing technology):

Condition	Detection Rate	False Positive Rate
Trisomy 21 (Down syndrome)	>99%	<0.1%
Trisomy 18 (Edwards syndrome)	>97%	<0.1%
Trisomy 13 (Patau syndrome)	>92%	<0.1%
Sex chromosome aneuploidies	~90–95%	<0.5%

Note that NIPT is a screening test, not a diagnostic one. A positive result should be confirmed with CVS or amniocentesis. The positive predictive value (PPV) depends on the prevalence of the condition in the population—for example, PPV for trisomy 21 is very high in women over 35, but lower for rare microdeletions.

Factors That Affect Accuracy

Several variables influence the reliability of NIPT results:

Fetal fraction: The proportion of cell-free DNA from the placenta. Most labs require a minimum of 4% fetal fraction; lower fractions can lead to test failure or false negatives. Factors like maternal weight and gestational age affect fetal fraction.
Gestational age: NIPT is validated from 10 weeks onward. Testing too early may yield insufficient fetal DNA.
Multiple pregnancies: In twin or higher-order pregnancies, accuracy may be slightly reduced, and the test cannot always determine which fetus is affected.
Maternal conditions: Rare maternal chromosomal abnormalities (e.g., mosaicism) or a history of organ transplant can interfere with results.
Laboratory quality: Reputable US labs adhere to strict CLIA and CAP standards, but variability exists. Always choose a lab with published validation data.

Comparing NIPT to Other Prenatal Screening Tests

Other screening options exist, but they generally have lower accuracy than NIPT:

First-trimester screening: Combines ultrasound (nuchal translucency) and blood biomarkers (PAPP-A, hCG). Detection rate for Down syndrome is about 85% with a 5% false positive rate.
Quad screen (second trimester): Measures four serum markers. Detection rate ~80% for Down syndrome.
Integrated screening: Combines first- and second-trimester results, achieving ~90% detection but requiring multiple visits.
Carrier screening: Tests parents for recessive genetic conditions (e.g., cystic fibrosis, fragile X, SMA). It is not a fetal DNA test but is often offered alongside NIPT as part of a comprehensive prenatal screening panel.

NIPT’s superior accuracy has made it the recommended first-line screening for all pregnant individuals, regardless of age, according to major US medical societies (2026 guidelines).

Diagnostic Tests vs. Screening

If NIPT returns a high-risk result, diagnostic procedures like chorionic villus sampling (CVS) or amniocentesis can confirm the finding. CVS is performed at 10–13 weeks, amniocentesis at 15–20 weeks. Both carry a small risk of miscarriage (approximately 0.1–0.3%). A genetic counselor can help you interpret results and decide on follow-up.

What to Do With Your Results

Understanding your NIPT result requires context. A “low risk” result does not guarantee a healthy baby—it only rules out the specific conditions tested. A “high risk” result does not confirm a diagnosis. Always discuss results with a genetic counselor, who can explain the positive predictive value and recommend next steps, such as diagnostic testing or additional ultrasound.

Ordering a Comprehensive Prenatal Screening Panel

For a complete picture of fetal health, many US providers now offer a combined panel that includes NIPT for chromosomal abnormalities plus carrier screening for common recessive conditions. This approach gives you actionable information early in pregnancy without the need for multiple separate tests. If you are ready to take the next step, you can order a prenatal screening panel online and receive results within 5–7 business days. The process is simple: a blood draw at a local lab, followed by a secure online report with guidance from a genetic counselor.